Pages that link to "Q33494051"

The following pages link to Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months (Q33494051):

Displaying 30 items.

• Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S (Q24621867) (← links)
• Perinatal systemic gene delivery using adeno-associated viral vectors (Q26852989) (← links)
• The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement (Q28182540) (← links)
• Gaucher disease: transcriptome analyses using microarray or mRNA sequencing in a Gba1 mutant mouse model treated with velaglucerase alfa or imiglucerase (Q28534109) (← links)
• Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease (Q33348492) (← links)
• An overview on bone manifestations in Gaucher disease (Q33393590) (← links)
• Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment (Q33403298) (← links)
• Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease (Q33568987) (← links)
• Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model (Q33588593) (← links)
• Enzyme replacement therapy for Gaucher's disease: the early Canadian experience (Q34030086) (← links)
• Bone and joint complications related to Gaucher disease (Q34108919) (← links)
• Clinically relevant therapeutic endpoints in type I Gaucher disease. (Q34471681) (← links)
• Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications (Q34485240) (← links)
• Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone (Q34799677) (← links)
• Enzyme replacement and enhancement therapies for lysosomal diseases (Q35800534) (← links)
• Enzyme replacement in a canine model of Hurler syndrome (Q36013555) (← links)
• Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. (Q37221766) (← links)
• Review of the safety and efficacy of imiglucerase treatment of Gaucher disease (Q37354438) (← links)
• Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation (Q37365631) (← links)
• Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy (Q37383736) (← links)
• Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment (Q37718650) (← links)
• Current issues in enzyme therapy for Gaucher disease (Q41139731) (← links)
• Alglucerase (Ceredase). (Q41155575) (← links)
• The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study (Q50872092) (← links)
• Quality of life assessment in adults with type 1 Gaucher disease. (Q53542726) (← links)
• Resolution of a proximal humeral defect in type-1 Gaucher disease by enzyme replacement therapy (Q71567529) (← links)
• Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase (Q73614095) (← links)
• Improvement of splenomegaly and pancytopenia by enzyme replacement therapy against type 1 Gaucher disease: a report of sibling cases (Q73855695) (← links)
• Oligosaccharide excretion in adult Gaucher disease (Q74311660) (← links)
• Alglucerase for Gaucher's disease: dose, costs and benefits (Q74823701) (← links)